These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 34417136)
1. Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer. Dhere VR; Fischer-Valuck BW; Goyal S; Liu Y; Morgan TM; Ghavidel E; Moghanaki DM; Hershatter BW; Patel PR; Jani AB; Godette KD; Rossi PJ; Patel SA Brachytherapy; 2021; 20(6):1130-1138. PubMed ID: 34417136 [TBL] [Abstract][Full Text] [Related]
2. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer. Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045 [TBL] [Abstract][Full Text] [Related]
3. A Randomized Trial Comparing Quality of Life After Low-Dose Rate or High-Dose Rate Prostate Brachytherapy Boost With Pelvic External Beam Radiation Therapy. Crook J; Moideen N; Arbour G; Castro F; Araujo C; Batchelar D; Halperin R; Hilts M; Kim D; Petrik D; Rose J; Cheng JC; Bachand F Int J Radiat Oncol Biol Phys; 2024 Sep; 120(1):59-68. PubMed ID: 38493901 [TBL] [Abstract][Full Text] [Related]
4. Combined brachytherapy and ultra-hypofractionated radiotherapy for intermediate-risk prostate cancer: Comparison of toxicity outcomes using a high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy boost. Kollmeier MA; Gorovets D; Flynn J; McBride S; Brennan V; Beaudry J; Cohen G; Damato A; Zhang Z; Zelefsky MJ Brachytherapy; 2022; 21(5):599-604. PubMed ID: 35725549 [TBL] [Abstract][Full Text] [Related]
5. Impact of High-Dose-Rate and Low-Dose-Rate Brachytherapy Boost on Toxicity, Functional and Cancer Outcomes in Patients Receiving External Beam Radiation Therapy for Prostate Cancer: A National Population-Based Study. Parry MG; Nossiter J; Sujenthiran A; Cowling TE; Patel RN; Morris M; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1219-1229. PubMed ID: 33279595 [TBL] [Abstract][Full Text] [Related]
6. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432 [TBL] [Abstract][Full Text] [Related]
7. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer. Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146 [TBL] [Abstract][Full Text] [Related]
8. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer. Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M Brachytherapy; 2018; 17(3):517-523. PubMed ID: 29496423 [TBL] [Abstract][Full Text] [Related]
9. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838 [TBL] [Abstract][Full Text] [Related]
10. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653 [TBL] [Abstract][Full Text] [Related]
11. High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer. Yamazaki H; Masui K; Suzuki G; Aibe N; Shimizu D; Kimoto T; Yamada K; Ueno A; Matsugasumi T; Yamada Y; Shiraishi T; Fujihara A; Okihara K; Yoshida K; Nakamura S Sci Rep; 2021 Mar; 11(1):6165. PubMed ID: 33731856 [TBL] [Abstract][Full Text] [Related]
12. Population-based patient-reported quality of life outcomes following low-dose-rate versus high-dose-rate brachytherapy monotherapy for low-intermediate risk prostate cancer. Ong WL; Evans M; Papa N; Williams S; Millar J J Med Imaging Radiat Oncol; 2023 Oct; 67(7):789-795. PubMed ID: 37828817 [TBL] [Abstract][Full Text] [Related]
13. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis. Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone. Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848 [TBL] [Abstract][Full Text] [Related]
15. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity. Ishiyama H; Kitano M; Satoh T; Kotani S; Uemae M; Matsumoto K; Okusa H; Tabata K; Baba S; Hayakawa K Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):23-8. PubMed ID: 19243900 [TBL] [Abstract][Full Text] [Related]
16. Timing of High-Dose-Rate Brachytherapy With External Beam Radiation Therapy in Patients With Intermediate- and High-Risk Localized Prostate Cancer and Its Effects on Toxicity and Quality of Life: A Randomized Controlled Trial (THEPCA). Choudhury M; Thomas SS; Cain A; Palvai S; Nageshwaran S; Zhang J; Hayden K; Cain A; Hoskin P; Ahmed I Int J Radiat Oncol Biol Phys; 2024 May; 119(1):90-99. PubMed ID: 38163520 [TBL] [Abstract][Full Text] [Related]
17. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839 [TBL] [Abstract][Full Text] [Related]
18. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980 [TBL] [Abstract][Full Text] [Related]
19. Acute patient-reported bowel quality of life and rectal bleeding with the combination of prostate external beam radiation, low-dose-rate brachytherapy boost, and SpaceOAR. Patel AK; Houser C; Benoit R; Smith RP; Beriwal S Brachytherapy; 2020; 19(4):477-483. PubMed ID: 32331976 [TBL] [Abstract][Full Text] [Related]
20. Radiotherapy in localized prostate cancer: a multicenter analysis evaluating tumor control and late toxicity after brachytherapy and external beam radiotherapy in 1293 patients. Moll M; Nechvile E; Kirisits C; Komina O; Pajer T; Kohl B; Miszczyk M; Widder J; Knocke-Abulesz TH; Goldner G Strahlenther Onkol; 2024 Aug; 200(8):698-705. PubMed ID: 38488901 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]